	US 11,713,349 B2
	Ebola virus antibodies and binding agents derived therefrom
Rafi Ahmed, Atlanta, GA (US); Carl Davis, Atlanta, GA (US); and Erica Ollmann Saphire, Solana Beach, CA (US)
Assigned to Emory University, Atlanta, GA (US); and The Scripps Research Institute, La Jolla, CA (US)
Filed by Emory University, Atlanta, GA (US); and The Scripps Research Institute, La Jolla, CA (US)
Filed on Mar. 9, 2021, as Appl. No. 17/196,418.
Application 17/196,418 is a continuation of application No. 16/319,775, abandoned, previously published as PCT/US2017/043305, filed on Jul. 21, 2017.
Claims priority of provisional application 62/364,986, filed on Jul. 21, 2016.
Prior Publication US 2021/0221872 A1, Jul. 22, 2021
Int. Cl. C07K 16/10 (2006.01); C12Q 1/70 (2006.01); A61P 31/14 (2006.01)

CPC C07K 16/10 (2013.01) [A61P 31/14 (2018.01); C12Q 1/701 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/524 (2013.01); C07K 2317/71 (2013.01); C07K 2317/72 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

20 Claims

1. A non-naturally occurring chimeric antibody or antigen binding fragment comprising six complementarity determining regions (CDRs) of antibody 5.24.1C11,

wherein the CDRs comprise the three light chain CDRs, wherein light chain CDR 1 comprises the amino acid sequence of

	(SEQ ID NO: 134)
	QSLLHSNGYNY;

light chain CDR2 comprises the amino acid sequence of

	(SEQ ID NO: 135)
	LGSS;

light chain CDR3 comprises the amino acid sequence of

	(SEQ ID NO: 136)
	MQGLQTPLT;

and,

wherein the CDRs comprise the three heavy chain CDRs, wherein heavy chain CDR 1 comprises the amino acid sequence of

	(SEQ ID NO: 138)
	GYTFSSYNIH;

CDR 2 comprises the amino acid sequence of

	(SEQ ID NO: 139)
	PYGRSTT,

and CDR 3 comprises the amino acid sequence of

	(SEQ ID NO: 140)
	GRLYSGAPYGLDV,

and

wherein the antibody or antigen binding fragment thereof binds to an epitope expressed in an Ebola virus particle.